The functionalisation of therapeutic nanoparticle constructs with cancer-specific biomolecules can enable selective tumour accumulation and targeted treatment. Water soluble gold nanoparticles (ca. 4 nm) stabilised by a mixed monolayer of a hydrophobic zinc phthalocyanine photosensitiser (C11Pc) and hydrophilic polyethylene glycol (PEG) have been prepared. The C11Pc-PEG gold nanoparticle constructs were further functionalised with jacalin, a lectin specific for the cancer-associated Thomsen-Friedenreich (T) carbohydrate antigen, or with monoclonal antibodies specific for the human epidermal growth factor receptor-2 (HER-2). The two biofunctionalised nanoparticle conjugates produced similar levels of singlet oxygen upon irradiation at 633 nm. Importantly, both nanoparticle conjugates demonstrated extensive, yet comparable, phototoxicity in HT-29 colorectal adenocarcinoma cells (80-90%) and in SK-BR-3 breast adenocarcinoma cells (>99%). Non-conjugated C11Pc-PEG gold nanoparticles were only minimally phototoxic. Lysosomal colocalisation studies performed with the HT-29 colon cancer cells and the SK-BR-3 breast cancer cells revealed that both nanoparticle conjugates were partially localised within acidic organelles, which is typical of receptor-mediated endocytosis. The similarity of the targeted PDT efficacy of the two biofunctionalised C11Pc-PEG gold nanoparticles is discussed with respect to targeting ligand binding affinity and cell surface antigen density as key determinants of targeting efficiency. This study highlights how targeting small cell-surface molecules, such as the T antigen, can mediate a selective photodynamic treatment response 2 which is similar to that achieved when targeting overexpressed protein receptors, such as HER-2. The high prevalence of the T antigen present on the cellular surface of primary tumours emphasises the broad potential applications for lectin-targeted therapies.
Introduction
Photodynamic therapy (PDT) is based on the photochemical reaction between light and photosensitisers to generate therapeutic doses of cytotoxic singlet oxygen to efficiently treat cancers. 1 Recently, a broad range of studies have reported the improved therapeutic efficacy and enhanced pharmacokinetic behaviour of some photosensitising agents when coupled to nanoparticles. 2 Furthermore, nanoparticle systems can provide a robust platform for the conjugation of targeting agents in order to maximise the tumour selectivity of the photosensitiser-nanoparticle conjugate, while minimising any possible damage to healthy tissue. 2 Targeted nanoparticle platforms exhibit an additional advantage over conventional bioconjugates in that they display multivalent effects and enhanced tumour avidity through the existence of multiple targeting ligands at the surface of an individual nanoparticle entity. Antibodies are particularly attractive for targeted cancer treatment due to their high binding affinities with equilibrium dissociation constants (Kd) typically in the nanomolar range and also due to the broad range of pontential antigens. Antibody conjugates, so-called immunoconjugates, have seen wide-spread use for in vitro, in vivo and clinical cancer treatment. 4 Within PDT, a number of studies have reported the direct conjugation of a photosensitiser with a cancer-targeting antibody to generate photoimmunoconjugates for selective PDT treatment. 5 Levy et al. were the first to demonstrate the efficacy of using photoimmunoconjugates for targeted PDT. 6 This approach has since been adapted for a variety of antibodies, photosensitisers and bioconjugation techniques. 5 Recently, tumour-activatable photoimmunoconjugates composed of an anti-epidermal growth factor receptor (EGFR) antibody and a self-quenching photosensitiser benzoporphyrin derivative have been used to target in vivo OVCAR-5 human ovarian carcinomas overexpressing EGFR. 7 Multimodal treatment using this photoimmunoconjugate demonstrated a potent synergistic therapeutic effect through the downregulation of EGFR receptor signalling in addition to selective photodynamic destruction of tumour tissue.
Human epidermal growth factor receptor-2 (HER-2) is of the EGFR tyrosine kinase family of transmembrane receptors which modulates a number of processes including apoptosis, migration, proliferation, growth, adhesion and proliferation. 8 The HER-2 receptor is overexpressed in 10-34% of human breast cancers, and overexpression is correlated with poor disease prognosis. 9 HER-2 overexpression directly increases cancer cell proliferation and migration, and also results in resistance to therapy and apoptotic induction. 8 The HER-2 receptor is targeted in the clinic using the therapeutic monoclonal antibody trastuzumab (Herceptin), in particular for the treatment of HER-2 positive breast cancers. 10 We have previously targeted human breast cancer cells that over-express the HER-2 receptor using zinc phthalocyaninepolyethylene glycol (C11Pc-PEG) stabilised gold nanoparticles conjugated to monoclonal anti-HER-2 antibodies. 11 Following irradiation, the antibody functionalised nanoparticles selectively reduced the viability of HER-2 overexpressing cells. MDA-MB-231 breast cancer cells not expressing the HER-2 receptor and subnormal, non-transformed MCF-10A breast epithelial cells were largely unaffected by the HER-2 targeted PDT treatment. 11 An alternative cell surface target is the folate receptor. This receptor is overexpressed in more than 90% of human ovarian carcinoma cells and has therefore been extensively targeted with folate-chemotherapeutic conjugates to selectively deliver anti-cancer agents to tumour cells. 12 One of the earliest reported studies showed the effective folate targeting of KB human nasopharyngeal cancer cells using a folate-conjugated liposomal preparation of chloroaluminium phthalocyanine. 13 More recently, folate modified porphysome structures have been described, that upon binding to tumour cell folate receptors, destabilise and become activated thus enabling their photosensitising potential. 14 Likewise, transferrin bioconjugates have been widely used for monitoring disease progression and for the targeted destruction of cancer cells overexpressing the transferrin receptor. 15 The first example of transferrin targeted PDT was reported by Hamblin and Newman who demonstrated that a transferrin-haematoporphyrin conjugate exhibited a superior PDT efficacy in HT-29 colon cancer and NIH:3T3 cells, as compared to an albumin-haematoporphyrin conjugate. 16 A number of oligopeptides with specific affinities towards cancer-associated targets have been identified as powerful cancer-targeting biomolecules. These include peptides containing the arginine-glycine-aspartate (RGD) sequence which target αvβ3 and αvβ5 integrins that are overexpressed by a number of cancer cells and activated angiogenic vascular endothelial cells. 17 The first evidence of the targeted PDT efficacy using RGD conjugates described the enhanced phototoxicity of RGD-containing adenoviral proteins conjugated to sulfonated aluminium phthalocyanines in integrin-expressing A549 lung and HeP2 laryngeal cancer cells. 18 Carbohydrates have also been used to directly target endogenous lectins (carbohydrate binding proteins) with expression patterns that correlate with neoplastic transformation. The first report of carbohydrate targeting for PDT described the conjugation, characterisation and in vitro assessment of the photosensitiser chlorin e6 conjugated to a galactosyl polymer. 19 More recently, mannose functionalised silica nanoparticles containing a porphyrin derivative photosensitiser have been used to target the specific lectin receptors overexpressed by human colorectal adenocarcinoma cells. 20 Targeting with mannose moieties doubled the PDT cytotoxicity of the silica nanoparticles in vitro and allowed for effective HCT-116 tumour reduction following in vivo PDT of a subcutaneous mouse model. Conversely, exogenous lectins, such as wheat germ agglutinin 21 and peanut agglutinin 22 have also been used for the targeting of cell surface carbohydrates that exhibit expression patterns that are associated with malignancy.
The Thomsen-Friedenreich carbohydrate antigen (T antigen) is a truncated O-linked oncofoetal glycan that is exposed in more than 90% of primary tumours. 23 The first report of using lectins for targeted photodynamic cancer therapy described the synthesis and PDT efficacy of a conjugate composed of the lectin, Morniga G, and a water soluble porphyrin photosensitiser. 24 PDT using the Morniga G-porphyrin conjugate, targeted towards the T antigen, reduced Jurkat leukaemia cell viability by more than 90%, whereas the non-conjugated sensitiser had no phototoxic effects at the same concentration. 24 We have previously shown that jacalin, a lectin specific for the T antigen, can selectively deliver C11Pc-PEG gold nanoparticles to HT-29 human colon adenocarcinoma cells that overexpress the T antigen. Targeted PDT treatment lead to an exceptional reduction in viability whereas incubation in the dark and non-targeted PDT treatment was largely non-cytotoxic. 25 In this present study, we compare, for the first time, the targeted PDT efficacy of C11Pc-PEG gold nanoparticles functionalised with either the lectin jacalin or with anti-HER-2 monoclonal antibodies. We demonstrate how targeting using lectins or antibodies can enhance PDT treatment response in both HT-29 colon cancer cells and in SK-BR-3 breast cancer cells, as compared to treatment with non-conjugated nanoparticles. We have shown that targeted PDT with jacalin or anti-HER-2 antibodies conjugated to our C11Pc-PEG nanoparticles induce similar levels of cytotoxicity. Our findings emphasise the importance of receptor density on cell surfaces in addition to the binding affinity of ligands for their respective targets when assessing potential targeting efficiency. With a high density of cancer-associated receptors on the cellular surface, the therapeutic value of weaker-binding targeting ligands may be significantly elevated. Finally, using confocal microscopy and lysosomal colocalisation studies, the internalisation mechanisms of the lectin or antibody nanoparticle conjugates in both cell lines have been analysed and found to be largely through the endocytic pathway.
Materials and Methods

Synthesis of the C11Pc-PEG gold nanoparticles and conjugation of targeting ligands
The synthesis and purification of the C11Pc-PEG gold nanoparticles was performed as previously reported. 25 Jacalin (Vector Laboratories) and monoclonal rat IgG2a anti-HER-2 antibodies (Abcam) were covalently conjugated to the PEG carboxyl groups on the C11Pc-PEG gold nanoparticles using N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide (EDC; Sigma-Aldrich) and N-hydroxysuccinimide (NHS; Fisher Scientific). The carboxyl moieties on the PEG were converted to amine-reactive NHS esters by stirring the C11Pc-PEG gold nanoparticles (2 ml, 6 μM C11Pc equivalent) for 30 min at room temperature in 50 mM MES buffer (pH 5.5, 0.05% Tween 20) with 2 mM EDC (0.8 μl, 0.877 g/ml) and 5 mM NHS (1.2 mg, 115.08 g/mol). Unreacted EDC and NHS were removed by ultrafiltration of the NHS-ester functionalised C11Pc-PEG gold nanoparticles in four separate 500 μl aliquots in Vivaspin TM 500 tubes (100 kDa molecular weight cut off (MWCO), polyethersulfone (PES); Sartorius Stedim Biotech). The ultrafiltration procedure was performed by centrifuging the nanoparticle samples in the Vivaspin TM 500 tubes at 14,300 xg for 30 min at 4°C. The NHS-ester functionalised C11Pc-PEG gold nanoparticles in two of the Vivaspin TM 500 tubes were each redispersed in 10 mM HEPES buffered saline (500 μl; pH 7.4, 150 mM NaCl, 100 μM CaCl2). The nanoparticle samples in the two remaining Vivaspin TM 500 tubes were each redispersed in 10 mM phosphate buffered saline (PBS, 500 µl; pH 7.4, 150 mM NaCl, 100 μM CaCl2.2H2O). Jacalin (15.87 µl, 1 mg.ml -1 ) was added to the NHS-ester functionalised C11Pc-PEG gold nanoparticles dispersed in the HEPES buffered saline (1 ml) and anti-HER-2 antibodies (18.51 µl, 1 mg.ml -1 ) were added to the nanoparticles dispersed in the PBS (1 ml). The HEPES and PBS 26 The jacalin or anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles prepared for use with the SK-BR-3 cells were redispersed in serum-free Dulbecco's Modified Eagle Medium (DMEM; Invitrogen) supplemented with 1 mM L-Gln, as previously described.
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As a control, non-conjugated C11Pc-PEG gold nanoparticles were also prepared in serum-free RPMI 1640 medium or serum-free DMEM medium, depending on the cell line used. All nanoparticle preparations were characterised using a Hitachi U-3010 UV-visible absorption spectrophotometer, appropriately diluted for in vitro experiments using either serum-free RPMI 1640 medium or serum-free DMEM medium, and stored at 4°C.
Singlet oxygen measurement of the jacalin conjugated or anti-HER-2 antibody conjugated
C11Pc-PEG gold nanoparticles
The production of singlet oxygen following the irradiation of jacalin conjugated or anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles was measured using the molecular probe anthracene-9,10-dipropionic acid disodium salt (ADPA, 366.32 g.mol -1 ; Molecular Probes). 27 The singlet oxygen production of both conjugates was compared to that of non-conjugated C11Pc-PEG. Non-conjugated, jacalin conjugated or anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles were centrifuged in 500 µl aliquots in Vivaspin TM 500 tubes at 14,300 xg for 30 min at 4°C. The nanoparticle samples were each redispersed in 10 mM PBS (500 µl; pH 7.4, 150 mM NaCl, 100 μM CaCl2.2H2O). The C11Pc-PEG gold nanoparticle preparations (450 µl) were individually placed in a 1.5 ml stoppered quartz cuvette with ADPA (50 µl, 1.7 mM in methanol) and a magnetic stirrer bar. The samples were irradiated at 633 nm for 30 min using a 10 mW Light intensity was measured using a Power Max 500AD Molectron power meter. The laser was positioned 50 cm above the cells. Following irradiation, the cells were incubated at 37 °C in a 5% CO2 atmosphere for 48 h. MTT reagent (10 µl, 5 mg.ml -1 in PBS) was added to each well and the cells were incubated at 37 °C in a 5% CO2 atmosphere for 4 h. The well contents were then removed and the formazan was dissolved in DMSO (200 µl). The well contents were transferred to transparent 96 well multidishes and the absorbance was measured at 550 nm using a MRXDynatech plate reader. Background absorbance at 550 nm of RPMI 1640 medium alone incubated with MTT reagent was subtracted from all measurements. Cell viability was calculated as a percentage of absorbance at 550 nm of untreated, non-irradiated HT-29. All assays were performed in triplicate. C11Pc equivalent, 1 ml). Following incubation with the nanoparticles, the cells were washed 3 times in PBS (1 ml) and finally kept in their respective media containing 10% FBS (2 ml). The cells were incubated for 15 h at 37 °C in a 5% CO2 atmosphere. Prior to imaging, the cells were incubated for 1 h with LysoSensor TM Green DND-189 (1 µM from 1 mM stock in DMSO; Invitrogen). The coverslips were mounted on a heated stage (37 °C) and 1 ml imaging medium (120 mM NaCl, 5 mM KCl, 2 mM CaCl2.2H2O, 1 mM MgCl2.4H2O, 1 mM NaH2PO4, 1 mM NaHCO3, 25 mM HEPES, 11 mM glucose, and 1 mg.ml -1 BSA) was added to each coverslip. The cells were 
Results
Preparation of photoactive lectin and antibody nanoparticle conjugates
Zinc phthalocyanine-polyethylene glycol (C11Pc-PEG) functionalised gold nanoparticles (ca. 4 nm) were synthesised as previously reported. 25 The synthetic procedure involved the reduction of gold chloride by sodium borohydride in the presence of both α-thio-ω-carboxy PEG and a thiolated 11-alkyl zinc phthalocyanine (C11Pc). The water soluble C11Pc-PEG gold nanoparticles (6 µM C11Pc equivalent) were covalently bound to jacalin or rat monoclonal anti-HER-2 IgG2a antibodies using EDC/NHS coupling. Based on the approximation that ca. 155 molecules of C11Pc were bound to each nanoparticle, a 6 μM solution of C11Pc-PEG gold nanoparticles contained ca.
38.7 nM gold nanoparticles. 25 By reacting a ca. 38.7 nM solution of EDC/NHS-activated C11Pc-PEG gold nanoparticles with 240 nM jacalin or anti-HER-2 antibodies the targeting ligands were at a 6.2-fold molar excess of gold nanoparticles. Therefore, it is thought that approximately 6
targeting ligands were present on each nanoparticle. Further, it was estimated that 65% of the PEG molecules on each nanoparticle remain unconjugated. 
Figure 1
Schematic representations of C11Pc-PEG gold nanoparticles covalently bound to A) jacalin or B) anti-HER-2 antibodies. The gold nanoparticles are depicted as the core spherical clusters, the PEG molecules are shown as black linear polymer molecules, and the C11Pc photosensitiser is shown as blue, surface-bound macrocyclic structures. Images of jacalin (PDB ID 1M26) 29 and the IgG2a antibody (PDB ID 1IGT) 30 were generated using PyMOL.
To compare the PDT efficiency of the jacalin conjugates with that of the anti-HER-2 antibody conjugates, the singlet oxygen production following the irradiation of the conjugated C11Pc-PEG gold nanoparticles was investigated. Non-conjugated C11Pc-PEG gold nanoparticles were used as a control. The production of singlet oxygen was measured in PBS using anthracene-9,10-dipropionic acid disodium salt (ADPA) as the colorimetric singlet oxygen probe. 27 ADPA exhibits characteristic absorption bands from 300-400 nm, which photobleach when the molecule reacts with singlet oxygen to produce an endoperoxide. The quantification of singlet oxygen was calculated using a 1:1 molar stoichiometry of singlet oxygen to ADPA. The number of moles of singlet oxygen produced were normalised to the concentration of C11Pc equivalent present in the nanoparticle samples. Figure 2 shows that there is no significant difference in the quantity of singlet oxygen produced following the irradiation of the C11Pc-PEG gold nanoparticles conjugated to either jacalin (Figure 2, green) or the anti-HER-2 antibody (Figure 2, blue) .
Following conjugation to either targeting proteins, the singlet oxygen production of the nanoparticle conjugates appears to be marginally less than that produced by the non-conjugated C11Pc-PEG gold nanoparticles (Figure 2, black) . However, the slight reduction in photoactivity following conjugation of the nanoparticles to either of the targeting ligands should be compensated by significantly enhanced cellular internalisation of the conjugates. Previously, we have shown that irradiation at 633 nm of 'control' (C11Pc-free) PEG gold nanoparticles (ca. 4 nm in diameter) in the presence of ADPA did not result in any photobleaching of ADPA, confirming that the C11Pc is essential for the production of singlet oxygen. 11
Figure 2
Singlet oxygen production following the irradiation at 633 nm of non-conjugated (black), jacalin conjugated (green) and anti-HER-2 antibody conjugated (blue) C11Pc-PEG gold nanoparticles. All nanoparticle samples were irradiated in 10 mM PBS (pH 7.4, 150 mM NaCl, 100 μM CaCl2.2H2O) in the presence of the colorimetric singlet oxygen molecular probe ADPA. 
Targeted PDT efficacy of the conjugated nanoparticles
We have reported previously the absorption, excitation and emission spectra of C11Pc assembled on gold nanoparticles. 31, 32 The absorption maximum of the phthalocyanine on the gold nanoparticles is ca. 690 nm. In this present study, with consideration of the convenience of using a Helium Neon laser, we excited the C11Pc-PEG gold nanoparticle conjugates within the cells at 633 nm. This wavelength is within the phthalocyanine absorption band envelope, and has been shown previously to be a suitable wavelength for the irradiation of anti-HER2 antibody or jacalin conjugated C11Pc-PEG nanoparticles within cancer cell lines.
11, 25
Additionally, to ensure that the lectin ligand targets the specific cell surface receptor, we have previously demonstrated that the targeted phototoxicity of the jacalin conjugated nanoparticles was competitively inhibited by the presence of the free sugar methyl-α-galactopyrannoside or the T antigen-expressing glycoprotein asialofetuin. 25 Similarly, the selectivity of anti-HER- However, this apparent improvement in PDT efficacy when targeting SK-BR-3 cells using the jacalin conjugates (0.10 μM C11Pc equivalent) was accompanied by a ca. 4% greater dark toxicity than when the cells were incubated with the anti-HER-2 antibody conjugates. within the endosomal compartments. 40, 41 Maturation of endosomes leads to their eventual acidification through combination with lysosomes via the endocytic degradation pathway. 42 Alternatively, internalised nanoparticles in the endosomes may be redirected to the extracellular domain prior to endosomal maturation and acidification. 43 Colocalisation of nanoparticle conjugates with acidic organelle markers would suggest that the conjugates are uptaken through an endocytic pathway rather than passive diffusion by which many lipophilic photosensitisers can enter cells. 42, 44 Acidic organelles within the HT-29 cells and SK-BR-3 cells were visualised using the green fluorescent marker LysoSensor TM Green DND-189 (1 µM) using excitation at 458 nm. The fluorescence of C11Pc upon excitation at 633 nm was exploited to visualise the conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent) within the intracellular environment.
Colocalisation of the nanoparticle conjugates with LysoSensor TM Green DND-189 was assessed using the BioImageXD software which correlates the red and green channels present in one voxel (volumetric pixel). Regions of colocalised red and green fluorescence from the conjugated C11Pc-PEG gold nanoparticles and the acidic organelles, respectively, were isolated and false coloured yellow. Figure 5 shows the laser scanning confocal microscope images of SK-BR-3 cells incubated with the jacalin conjugated C11Pc-PEG gold nanoparticles (Figure 5A , red) and LysoSensor TM Green DND-189 (Figure 5B, green) . For the image shown in Figure 5B the brightness of the green channel was reduced by 9% for clarity; however, colocalisation isolation and analysis using the BioImageXD software was performed on unaltered images. 
